Ischemic-lesion-site-specific gene therapy
The present invention provides an antisense nucleic acid medicine that can modulate expression of a target transcriptional product in an ischemic site of a subject. The present invention also provides a composition for modulating expression of a target transcriptional product in an ischemic site of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a lipid-conjugated second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.
1. A method for modulating expression of a target transcriptional product in an ischemic site of a subject, comprising administering a composition to the subject, wherein the composition comprises a nucleic acid complex formed by annealing together a first nucleic acid strand comprising an antisense oligonucleotide region with respect to the target transcriptional product, and a lipid-conjugated second nucleic acid strand comprising a complementary region that is complementary to at least part of the first nucleic acid strand; and wherein the target transcriptional product is an mRNA or an mRNA precursor.
2. The method according to claim 1 , wherein the first nucleic acid strand is from 9 to 50 bases in length.
3. The method according to claim 1 , wherein said antisense oligonucleotide region in the first nucleic acid strand is from 9 to 20 bases in length.
4. The method-according to claim 1 , wherein the second nucleic acid strand is from 9 to 50 bases in length.
5. The method according to claim 1 , wherein said complementary region in the second nucleic acid strand is complementary to at least part of said antisense oligonucleotide region in the first nucleic acid strand.
6. The method according to claim 1 , wherein the antisense oligonucleotide region is a gapmer type or mixmer type antisense oligonucleotide region.
7. The method according to claim 1 , wherein the lipid is tocopherol or an analog thereof, or cholesterol or an analog thereof.
8. The method according to claim 7 , wherein the lipid is cholesterol or an analog thereof.
9. The method according to claim 1 , wherein the ischemic site is located in a brain, cardiac muscle, or lower limb skeletal muscle.
10. The method according to claim 1 , wherein the administration is intravenous administration.
11. The method according to claim 1 , wherein the modulation of expression of a target transcriptional product is reduction of the amount of the target transcriptional product.
12. The method according to claim 1 , wherein the administration is an acute phase of ischemia.
13. The method according to claim 1 for treating an ischemic disease.
14. The method according to claim 13 , wherein the ischemic disease is ischemic stroke, myocardial infarction, or arteriosclerosis obliterans.
15. The method according to claim 13 , wherein the ischemic disease is a compressive ischemia, a traumatic ischemia or a thrombosis.
16. The method according to claim 13 , wherein the ischemic disease is an acute ischemic disease selected from the group consisting of cerebral venous sinus thrombosis, cerebral vasoconstriction syndrome, cerebral vasculitis, cerebral hemorrhage, subarachnoid hemorrhage, moyamoya disease, cerebral arteriovenous fistula, cerebral arteriovenous malformation, cervical/cerebral artery dissection, head trauma, brain contusion, brain tumor, coagulation disorder, congenital connective tissue disease, pulmonary infarction, splenic infarction, radiation vasculopathy, age-related vasculopathy, and drug-induced vasculopathy.
17. The method according to claim 13 , wherein the ischemic disease is a chronic ischemic disease selected from the group consisting of Fabry disease, cerebral amyloid angiopathy, traumatic disease, Buerger's disease, ischemic enteritis, diabetic peripheral neuropathy, and ischemic optic nerve disorder.